Biswas Susmito, Gaviria Martha, Malheiro Luísa, Marques João Pedro, Giordano Vincenzo, Liang Hong
Manchester Royal Eye Hospital and Manchester Academic and Health Sciences Centre, Manchester, UK.
University Hospital San Vicente Foundation, Medellín, Colombia.
Ophthalmol Ther. 2018 Dec;7(2):307-322. doi: 10.1007/s40123-018-0146-6. Epub 2018 Sep 21.
Cystinosis, a rare autosomal recessive disease caused by intracellular cystine accumulation, occurs in an estimated 1/100,000-200,000 live births. Ocular non-nephropathic cystinosis is typically diagnosed during adulthood, when patients present with corneal crystal deposition and no systemic involvement. Due to the rarity of the condition, diagnosis is often delayed and can have a significant impact on the overall prognosis of the disease. Early diagnosis is therefore imperative to ensure successful treatment and improve quality of life, as most of its clinical manifestations can be prevented or delayed. Early detection strategies and practical approaches for the ocular management of cystinosis were discussed during the Ophthalmology Cystinosis Forum, a 1-day meeting held in Berlin, Germany during June 2017. Recommendations for early detection comprise ophthalmic assessment, including self- and clinician-assessed recording of photophobia, and visual acuity, slit-lamp examination and tonometry ophthalmic examinations. In vivo confocal microscopy and anterior segment optical coherence tomography were highlighted as valuable techniques in evaluating cystine crystals in the cornea, in vivo and non-invasively. The mainstay of ocular cystinosis treatment is the cystine-depleting aminothiol cysteamine. Indeed, early treatment with and strict adherence to cysteamine therapy has a considerable impact on the long-term prognosis of ocular cystinosis. In rare diseases such as ocular cystinosis, standardised guidelines and recommendations for detection, patient care and follow-up assessments are essential. Such guidelines provide a support tool for healthcare professionals caring for ocular cystinosis patients. Multidisciplinary teams (MDTs) are essential for delivering gold standard care and improving quality of life for patients and their families. This review paper highlights current early detection policies, clinical treatment strategies and practical approaches for the ocular management of cystinosis, including implementing a cystinosis MDT. Additionally, discussions of the Ophthalmology Cystinosis Forum held in 2017 are summarised. FUNDING: Orphan Europe. Plain language summary available for this article.
胱氨酸贮积症是一种由细胞内胱氨酸蓄积引起的罕见常染色体隐性疾病,估计每10万至20万活产婴儿中就有1例发病。眼部非肾病性胱氨酸贮积症通常在成年期被诊断出来,此时患者会出现角膜晶体沉积且无全身受累情况。由于该病症罕见,诊断往往会延迟,这可能对疾病的总体预后产生重大影响。因此,早期诊断对于确保治疗成功和提高生活质量至关重要,因为其大多数临床表现是可以预防或延缓的。在2017年6月于德国柏林举行的为期1天的眼科胱氨酸贮积症论坛上,讨论了胱氨酸贮积症眼部管理的早期检测策略和实用方法。早期检测的建议包括眼科评估,其中有自我和临床医生评估的畏光记录、视力、裂隙灯检查和眼压测量等眼科检查。体内共聚焦显微镜检查和眼前节光学相干断层扫描被强调为在体内非侵入性评估角膜胱氨酸晶体的有价值技术。眼部胱氨酸贮积症治疗的主要手段是消耗胱氨酸的氨基硫醇半胱胺。事实上,早期使用半胱胺治疗并严格坚持该疗法对眼部胱氨酸贮积症的长期预后有相当大的影响。在诸如眼部胱氨酸贮积症这样的罕见疾病中,关于检测、患者护理和随访评估的标准化指南和建议至关重要。此类指南为护理眼部胱氨酸贮积症患者的医护人员提供了一种支持工具。多学科团队对于提供金标准护理以及改善患者及其家庭的生活质量至关重要。这篇综述文章重点介绍了当前胱氨酸贮积症眼部管理的早期检测政策、临床治疗策略和实用方法,包括实施胱氨酸贮积症多学科团队。此外,还总结了2017年举行的眼科胱氨酸贮积症论坛的讨论内容。资助:欧洲孤儿药公司。本文提供了通俗易懂的摘要。